DE60218710D1 - Gen und protein mit bezug zu hepatozellulärem karzinom - Google Patents

Gen und protein mit bezug zu hepatozellulärem karzinom

Info

Publication number
DE60218710D1
DE60218710D1 DE60218710T DE60218710T DE60218710D1 DE 60218710 D1 DE60218710 D1 DE 60218710D1 DE 60218710 T DE60218710 T DE 60218710T DE 60218710 T DE60218710 T DE 60218710T DE 60218710 D1 DE60218710 D1 DE 60218710D1
Authority
DE
Germany
Prior art keywords
gene
hepatocellular carcinoma
protein related
protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60218710T
Other languages
English (en)
Other versions
DE60218710T2 (de
Inventor
Yusuke Nakamura
Yoichi Furukawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2399569 external-priority patent/CA2399569A1/en
Application filed by Oncotherapy Science Inc, University of Tokyo NUC filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of DE60218710D1 publication Critical patent/DE60218710D1/de
Publication of DE60218710T2 publication Critical patent/DE60218710T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809Methods for determination or identification of nucleic acids involving differential detection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE2002618710 2001-09-25 2002-09-25 Gen und protein mit bezug zu hepatozellulärem karzinom Expired - Lifetime DE60218710T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32426101P 2001-09-25 2001-09-25
US324261P 2001-09-25
US39166602P 2002-06-26 2002-06-26
US391666P 2002-06-26
CA 2399569 CA2399569A1 (en) 2001-09-25 2002-08-23 Diagnostic markers and drug targets for treatment of cancer
CA2399569 2002-08-23
PCT/JP2002/009876 WO2003027143A2 (en) 2001-09-25 2002-09-25 Gene and protein relating to hepatocellular carcinoma

Publications (2)

Publication Number Publication Date
DE60218710D1 true DE60218710D1 (de) 2007-04-19
DE60218710T2 DE60218710T2 (de) 2007-12-06

Family

ID=27171637

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2002618710 Expired - Lifetime DE60218710T2 (de) 2001-09-25 2002-09-25 Gen und protein mit bezug zu hepatozellulärem karzinom

Country Status (9)

Country Link
US (3) US7767392B2 (de)
EP (1) EP1430152B1 (de)
JP (1) JP4353798B2 (de)
CN (1) CN1628179B (de)
AT (1) ATE356223T1 (de)
AU (1) AU2002329061A1 (de)
DE (1) DE60218710T2 (de)
ES (1) ES2283592T3 (de)
WO (1) WO2003027143A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4353798B2 (ja) 2001-09-25 2009-10-28 オンコセラピー・サイエンス株式会社 肝細胞癌に関連する遺伝子およびタンパク質
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
ES2363500T3 (es) * 2003-02-28 2011-08-05 Oncotherapy Science, Inc. Arn interferente para el gen znfn3a1 como método para inhibir el crecimiento de células cancerosas.
JP2007506425A (ja) * 2003-09-24 2007-03-22 オンコセラピー・サイエンス株式会社 肝細胞癌を診断する方法
TWI350373B (en) * 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
US20060189560A1 (en) * 2005-01-27 2006-08-24 Ajit Kumar Molecular method to augment RNA mediated gene silencing
EP1866436A1 (de) * 2005-02-28 2007-12-19 Oncotherapy Science, Inc. Mit brustkrebs verbundenes gen znfn3a1
WO2006121208A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Polymorphisms of the e2f-1 binding element and methods of determining cancer susceptibility
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
JP5272134B2 (ja) 2007-06-14 2013-08-28 オンコセラピー・サイエンス株式会社 Smyd3によるvegfr1のメチル化調整因子を同定する方法
JP5704570B2 (ja) 2009-03-05 2015-04-22 独立行政法人産業技術総合研究所 肝内胆管がんの検出、判別方法
WO2011011366A2 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
JP6051373B2 (ja) 2011-12-02 2016-12-27 オンコセラピー・サイエンス株式会社 癌の治療および診断の標的遺伝子としてのsmyd2
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039200A1 (en) 1998-01-29 1999-08-05 Thomas Jefferson University Molecular markers for diagnosing hepatocellular carcinoma
US6783961B1 (en) 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
WO2000017355A2 (en) 1998-09-18 2000-03-30 Incyte Pharmaceuticals, Inc. Human cytoskeleton associated proteins
EP1144625A2 (de) * 1999-01-29 2001-10-17 Incyte Pharmaceuticals, Inc. Nukleinsäure bindende proteine
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2001029221A2 (en) 1999-10-20 2001-04-26 Zymogenetics, Inc. Proteins and polynucleotides encoding them
EP1240178A4 (de) 1999-12-23 2004-06-30 Nuvelo Inc VERFAHREN UND MATERIALIEN MIT BEZUG ZU PROTHROMBINASE-äHNLICHEN POLYPEPTIDEN UND POLYNUKLEOTIDEN.
EP1591448A3 (de) 2000-04-18 2006-01-11 Nuvelo, Inc. Neue Nukleinsäuren und Polypeptiden
WO2002059377A2 (en) 2001-01-24 2002-08-01 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
GB0111218D0 (en) 2001-05-08 2001-06-27 Cancer Res Ventures Ltd Assays methods and means
AU2002309750A1 (en) 2001-05-11 2002-11-25 The Burnham Institute Screening, diagnostic and therapeutic methods relating to riz
CA2936534C (en) 2001-07-23 2021-01-26 The Board Of Trustees Of Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
JP4353798B2 (ja) * 2001-09-25 2009-10-28 オンコセラピー・サイエンス株式会社 肝細胞癌に関連する遺伝子およびタンパク質
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
JP2005512529A (ja) * 2001-12-13 2005-05-12 エクセリクシス・インコーポレイテッド βカテニン経路のモディファイヤーとしてのTAOJIKsおよび使用方法
ES2363500T3 (es) 2003-02-28 2011-08-05 Oncotherapy Science, Inc. Arn interferente para el gen znfn3a1 como método para inhibir el crecimiento de células cancerosas.
TWI350373B (en) 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
EP1866436A1 (de) 2005-02-28 2007-12-19 Oncotherapy Science, Inc. Mit brustkrebs verbundenes gen znfn3a1
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
JP5272134B2 (ja) * 2007-06-14 2013-08-28 オンコセラピー・サイエンス株式会社 Smyd3によるvegfr1のメチル化調整因子を同定する方法

Also Published As

Publication number Publication date
JP2005511023A (ja) 2005-04-28
DE60218710T2 (de) 2007-12-06
EP1430152B1 (de) 2007-03-07
CN1628179B (zh) 2011-04-20
WO2003027143A2 (en) 2003-04-03
ES2283592T3 (es) 2007-11-01
US8148080B2 (en) 2012-04-03
US7767392B2 (en) 2010-08-03
US20120149762A1 (en) 2012-06-14
ATE356223T1 (de) 2007-03-15
WO2003027143A3 (en) 2003-10-30
US20100248240A1 (en) 2010-09-30
EP1430152A2 (de) 2004-06-23
CN1628179A (zh) 2005-06-15
AU2002329061A1 (en) 2003-04-07
US20040235018A1 (en) 2004-11-25
JP4353798B2 (ja) 2009-10-28

Similar Documents

Publication Publication Date Title
DE60218710D1 (de) Gen und protein mit bezug zu hepatozellulärem karzinom
LTPA2015049I1 (lt) Žpv 45 l1 optimizuota ekspresija mielėse
ATE402188T1 (de) Bindungsproteine als biosensoren
DE50306809D1 (de) Verwendung von nativem zein zur verbesserung des haarzustandes und mittel
ATE445402T1 (de) Neue verwendung von pde5-hemmern
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
HUE044812T2 (hu) Prolinspecifikus endoproteázok alkalmazása peptidek és fehérjék hidrolízisére
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
EP1697741A4 (de) Verfahren zur erzeugung von proteinvarianten mit erhöhtem wirtsstranggehalt und zusammensetzungen davon
ATE502053T1 (de) Rekombinanter, tumorspezifischer antikörper und dessen verwendung
IL199414A0 (en) Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibodies and other binding agents
ATE473279T1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
DE60129572D1 (de) Verwendung von antikörpern gegen spezifische mhc-peptidkomplexe
SE0302304D0 (sv) Novel compounds
WO2006016525A3 (en) Genes and polypeptides relating to breast cancers
DE60322898D1 (de) Verwendung von isoflavonen zur förderung des schlankheitseffekts
EP1546182A4 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
DE60101559D1 (de) Benutzung von comt-inhibitoren als analgetika
ATE513040T1 (de) Zinkfingerdomänenbibliotheken
ATE415961T1 (de) Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7- dimethylbicycloä2.2.1ühept-1- ylmethanesulphonamide-familie
SG147469A1 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
ATE441712T1 (de) Die nukleotidsequenz ann bindende zink-finger domänen
DE60201337D1 (de) Kontinuierliche umesterung von alkoxysilanen
BR0012675A (pt) Uso de inibidores de il-18
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ONCOTHERAPY SCIENCE, INC., KAWASAKI, KANAGAWA, JP

8364 No opposition during term of opposition